<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03727737</url>
  </required_header>
  <id_info>
    <org_study_id>ADANEW_0001</org_study_id>
    <nct_id>NCT03727737</nct_id>
  </id_info>
  <brief_title>Efficacy of Repetitive Transcranial Magnetic Stimulation for Improvement of Memory in Older Adults With TBI</brief_title>
  <acronym>ADANEW_0001</acronym>
  <official_title>Efficacy of Repetitive Transcranial Magnetic Stimulation for Improvement of Memory in Older Adults With TBI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Palo Alto Veterans Institute for Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Defense and Veterans Brain Injury Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Palo Alto Veterans Institute for Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study will evaluate the safety, durability and efficacy of repetitive
      Transcranial Magnetic Stimulation (rTMS) as a promising non-invasive therapeutic treatment
      for improving memory in older adults with mild or moderate Traumatic Brain Injury (TBI) who
      have been experiencing residual memory or cognitive problems that affect daily functioning.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent advances in both AD and TBI test non-pharmaceutical interventions that target chronic
      symptom improvement (e.g., non- invasive brain stimulation, exercise and cognitive training).
      In order to provide targeted therapies to patients who suffer from chronic sequela of TBI it
      is necessary to understand mechanisms of repair within the context of an aging brain.
      Repetitive TMS (rTMS) delivers therapeutic, noninvasive brain stimulation, is FDA-approved
      for treatment for major depression and currently used for treatment of pain, PTSD, anxiety,
      improvement of executive function in mild and moderate TBI, severe TBI, memory enhancement
      and dementia.

      This treatment can induce neuronal long-term potentiation resulting in synaptic repair
      leading to improvements in memory function through hippocampal- cortical circuits and brain
      connectivity measured by resting state-fMRI (rs fMRI) particularly in default mode and
      central executive network (DMN &amp; CEN). The study primarily proposes to assess the efficacy of
      rTMS to improve memory performance and to test rs-fMRI (i.e. DMN) as a potential biomarker to
      capture response to treatment in older patients suffering with chronic symptoms related to
      previous brain injuries (depression, PTSD etc). In addition, the study will assess other
      established biomarkers longitudinally (e.g.,hypometabolism via PET FDG, cortical oscillation
      via electroencephalography (EEG), Brain Derived Nerve Growth Factor (BDNF)and hippocampal
      volume from structural MRI) to capture patient response to treatment that may signal early
      dementia.

      HYPOTHESES:

      Primary:

      Subjects with TBI who receive active rTMS treatment (rTMS_A) will: a) show significantly
      greater improvement from baseline in memory performance post rTMS intervention compared to
      subjects who received sham rTMS treatment (rTMS_S), and b) show stronger functional
      connectivity within and between DMN and CEN post rTMS intervention compared to patients who
      received sham (rTMS_S).

      Secondary:

        1. Quality of Life (QOL): scores on QOL scale will improve with rTMS treatment in patients
           who receive rTMS treatment.

        2. Sustained Improvement: At 6-month follow-up, patients with TBI in rTMS_A group would be
           more likely to have sustained greater brain connectivity compared to patients in the
           rTMS_S group predicting better memory performance.

        3. Moderators of Response: The following variables may moderate memory function improvement
           in patients with TBI post intervention and at 6-month follow-up: Age, health condition
           variables (severity of symptoms at baseline, time to injury, baseline cognitive
           performance, TBI type,comorbidities (PTSD, sleep, depression), substance abuse,
           medication use, fatigue); physiological and biological variables (baseline hippocampal
           volume and/or microstructure, baseline connectivity in DMN &amp; CEN, EEG resting and
           task-related cortical oscillations, and Brain Derived Neurotrophic Factor (BDNF)
           genotype.

        4. Mediators of Response: To assess the mechanism of rTMS in synaptic repair/regeneration,
           pre and post changes will be assessed in depression and PTSD measures, Plasma BDNF, FDG
           PET hypometabolism in precuneus/posterior cingulate area, EEG resting and task-related
           cortical oscillations, and connectivity of DLPFC (stimulation site &amp; part of CEN) with
           other DMN.

      SPECIFIC OBJECTIVES:

      Primary Objective: a) To assess the efficacy of rTMS to predict improvement in memory
      performance pre and post rTMS intervention in older patients with TBI, and b) To assess
      rs-fMRI as a biomarker to detect these changes in memory performance.

      Secondary Objective: To assess the mechanism of rTMS in synaptic repair/regeneration by
      assessment of structure &amp; functional brain activity (PET/MRI, fMRI, &amp; EEG), genetic,
      cognitive and behavioral function factors (including QOL, depression and PTSD).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 23, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The proposed study will evaluate the safety, durability and efficacy of repetitive Transcranial Magnetic Stimulation (rTMS) as a promising non-invasive therapeutic treatment for improving memory in older adults with mild or moderate Traumatic Brain Injury (TBI) who have been experiencing residual memory or cognitive problems that affect daily functioning.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>double blind study until trial is complete</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>CANTAB Paired Associates Learning (PAL)</measure>
    <time_frame>2-4 weeks</time_frame>
    <description>Test for visual memory and new learning: it is a hippocampal-mediated paired associates learning task. This test has twenty-one outcome measures, covering the errors made by the participant, the number of trials required to locate the pattern(s) correctly, memory scores and stages completed (Administration time 10 minutes). The main score provided is the sum of pairs reproduced over three trials (range: 0-30). We will use the average number of trials needed to succeed on PAL task as the main outcome measure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional Connectivity Changes in the Brain</measure>
    <time_frame>2-4 weeks</time_frame>
    <description>Neuroimaging using PET/MRI to determine Functional Connectivity in Default Mode Network (DMN) and Central Executive Network (CEN) systems in the brain following rTMS treatment. we will do this by doing ICA analysis for each network focused from the stimulation site.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Quality of Life measure: Short Form of Veterans Rand 36 Item Health Survey (SF/VR-36)</measure>
    <time_frame>2-4 weeks</time_frame>
    <description>Measure of Quality of Life change following rTMS treatment. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. We will look at these standardized eight scores as outcomes measures as well as a total composite score as an outcome measure.</description>
  </other_outcome>
  <other_outcome>
    <measure>Sustained Improvement in primary Outcome Measure (CANTAB Paired Associates Learning (PAL)) at 6 months post-treatment</measure>
    <time_frame>6 months</time_frame>
    <description>At 6-month follow-up, the study primary outcome, CANTAB Paired Associate Learning task will be assessed again to identify changes that are sustained due to treatment at six-months. This test has twenty-one outcome measures, covering the errors made by the participant, the number of trials required to locate the pattern(s) correctly, memory scores and stages completed (Administration time 10 minutes). The main score provided is the sum of pairs reproduced over three trials (range: 0-30). We will use the average number of trials needed to succeed on PAL task as the main outcome measure.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Brain Injuries, Traumatic</condition>
  <condition>Repetitive Transcranial Magnetic Stimulation</condition>
  <condition>Memory Deficits</condition>
  <condition>Aging</condition>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients with mild and moderate TBI will be assigned randomly to this arm and will not receive treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACTIVE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with mild and moderate TBI will be assigned randomly to this arm and will receive treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Repetitive Transcranial magnetic Stimulation</intervention_name>
    <description>RTMS will be delivered via magventure machine, on an approved FDA IDE protocol to DLPFC region to improve memory in older adults (veterans and non-veterans) with mild and moderate TBI.</description>
    <arm_group_label>ACTIVE</arm_group_label>
    <other_name>rTMS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 50-75 years, with a high school education

          -  History of mild or moderate TBI as defined by the DoD/VA Clinical Practice Guidelines
             for Definition of TBI

          -  Ability to obtain a Motor Threshold (MT) will be determined during the screening
             process

          -  Must be in the chronic stable phase of recovery (&gt;6 months post injury) with residual
             cognitive difficulties that are affecting daily functioning (including self-reported
             memory or cognition problems)

          -  If on a psychotropic medication regimen, that regimen will be stable for at least 4
             weeks prior to entry to the study and patient will be willing to remain on a stable
             regimen during the acute treatment phase

          -  Has an adequately stable condition and environment to enable attendance at scheduled
             clinic visits

          -  For female participants of child bearing potential, agrees to use one of the following
             acceptable methods of birth control: abstinence, oral contraceptive, Norplant,
             Depo-Provera, a condom with spermicide, a cervical cap with spermicide, a diaphragm
             with spermicide, an intrauterine device, surgical sterilization (having your tubes
             tied)

          -  Able to read, verbalize understanding, and voluntarily sign the Informed Consent Form
             prior to participating in any study-specific procedures or assessments

          -  Individuals who meet the study criteria but have impaired decision making capacity may
             participate provided they are able to voluntarily sign an Assent Form and have an LAR
             who can sign a Consent Form and accompany the participant to all study visits

        Exclusion Criteria:

          -  Diagnosed with Dementia

          -  Pregnant or lactating female.

          -  Unable to be safely withdrawn, at least two-weeks prior to beginning treatment, from
             medications that substantially increase the risk of seizures

          -  Have a cardiac pacemaker or a cochlear implant

          -  Have an implanted device (deep brain stimulation) or metal in the brain (see standard
             MRI exclusion criteria including metal screening section in telephone screen, Appendix
             A)

          -  Have a mass lesion, cerebral infarct or other active CNS disease, including a seizure
             disorder

          -  Known current psychosis as determined by DSM-IV coding in chart (Axis I, psychotic
             disorder, schizophrenia) or a history of a non-mood psychotic disorder

          -  Diagnosis of Bipolar Affective Disorder I (as determined by chart review and intake
             interview), since this in conjunction with TBI increases seizure risk

          -  Current amnesic disorders, dementia, MOCA â‰¤ 16, or delirium.

          -  Current substance abuse (not including caffeine or nicotine) as determined by positive
             toxicology screen, or by history via AUDIT, within 3 months prior to screening

          -  Prior history of seizures

          -  Severe TBI or open head injury

          -  TBI within last 6 months

          -  Participation in another concurrent clinical trial

          -  Patients with prior exposure to rTMS (NOTE: TMS is allowed) or ECT

          -  Active current suicidal intent or plan. Patients at risk for suicide will be required
             to establish a written safety plan involving their primary psychiatrist. All patients
             at risk for suicide will be excluded from the study (as per FDA recommendation).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Maheen M Adamson, PhD</last_name>
    <phone>6502136307</phone>
    <email>madamson@stanford.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Harlene Grewal</last_name>
    <phone>650-852-3233</phone>
    <email>Harlene.Grewal@va.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>VA Palo Alto Health Care System</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harlene Grewal, BA</last_name>
      <phone>650-852-3233</phone>
      <email>Harlene.Grewal@va.gov</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 23, 2018</study_first_submitted>
  <study_first_submitted_qc>October 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2018</study_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Palo Alto Veterans Institute for Research</investigator_affiliation>
    <investigator_full_name>Maheen M Adamson</investigator_full_name>
    <investigator_title>Senior Scientific Research Director, Defense and Veterans Brain Injury Center (DVBIC)</investigator_title>
  </responsible_party>
  <keyword>repetitive Transcranial Magnetic Stimulation</keyword>
  <keyword>Brain Injuries, Traumatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Memory Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

